Latent autoimmune diabetes iln adults (LADA) is the term used for patients with non-insulin dependent diabetes who progress to insulin dependency as their pancreatic secretion of insulin fails. Diagnosis is based on adult age at the time of diabetes, the presence of serum autoantibodies to pancreatic antigens and the absence of a requirement for insulin at diagnosis. High titres of serum glutamic acid decarboxylase (GAD) antibodies act as a marker for LADA. Serum C-peptide concentrations are also lower in autoimmune diabetic patients. The best treatment for patients with LADA is not clear, but early insulin treatment may prevent pancreatic b-cell failure.
Diabetes mellitus is a common cause of morbidity and premature loss of life. There are two main types of diabetes, type 1 and type 2. Although type 1 diabetes often develops in young patients, it can occur at any age. Type 1 diabetes is caused by an autoimmune process resulting in a destruction of the pancreatic insulinsecreting b-cells. Destruction of b-cells leads to hyperglycaemia due to a lack of insulin. The antibodies (glutamic acid decarboxylase [GAD] antibody and insulinoma-associated antigen [IA-2]) associated with this autoimmune reaction can be found in the blood. Type 2 diabetes most often develops in adults and is characterized by insu⁄cient insulin secretion, with insulin resistance.
In the UK Prospective Diabetes Study (UKPDS), approximately 10% of patients who appeared to have type 2 diabetes actually had antibodies to GAD and progressed to insulin dependency. 1,2 Among type 2 diabetic patients younger than 35 years of age at diagnosis, the frequency of this type of diabetes is approximately 25%. These (adult) patients, thus, have a slowly developing type 1 diabetes. They are initially non-insulin-requiring, but progress to insulin dependency as their pancreatic b-cell failure progresses. 3 The term latent autoimmune diabetes in adults (LADA) is often applied to these patients. Serum GAD antibodies act as a marker for the autoimmune damage associated with LADA. At a prevalence of 10%, this is a very common and important form of diabetes. 1, 2 
Detecting patients with latent autoimmune diabetes in adults
De¢ning LADA as a distinct form of diabetes is di⁄cult 4,5 as the pathogenesis is still unknown. Diagnosis of LADA is currently based on three criteria: adult age at the time of diabetes, the presence of circulating autoantibodies to pancreatic antigen and the absence of a requirement for insulin at diagnosis. More research is needed in order to de¢ne the defects present at the time of diagnosis and the development of the autoimmune disease. 4 Patients with LADA will have a stronger family history of both type 1 and type 2 diabetes, and will have a risk of other autoimmune conditions, 4,5 similar to patients with classical (rapid onset) type 1 diabetes. The extent of insulin resistance in LADA is debatable. Studies ¢nd insulin resistance to be much less than with type 2 diabetes, greater than recent onset classical type 1, but similar to that in type 1 diabetes with a long disease duration. 6--8 These ¢ndings suggest perhaps that LADA is a phenotype intermediate to type 1 and type 2 diabetes. However, depending on selection criteria, high levels of insulin resistance have been found in some populations of LADA patients. 5, 9 Currently serum GAD antibody tests are not routinely requested, so patients with LADA will often be treated as if they have type 2 diabetes. A clinical approach may often be successful in detecting LADA patients. 10 The correct diagnosis early in the disease might greatly reduce the level of morbidity associated with the diabetes for patients with LADA. However, the disease exists in the spectrum of autoimmune diabetes. 11 
Diagnosis
For diagnosis of type 1 diabetes, the presence of serum GAD antibodies has a sensitivity of 75% and a speci¢city of 100%. 12 The GAD antibody titre gives a probability of the patient's requirement for insulin. The higher the level, the faster and the more likely the progression to insulin dependence. For example, patients with a GAD of 101 units appear to have a 70% chance of being dependent on insulin within six years. 13 From 3867 patients in the UKPDS trial, 9.4% were autoantibody positive (islet cell cytoplasm, IA-2A, or GAD), with fasting plasma glucose between 6.1 and 14.9 mmol/L, and without symptoms associated with hyperglycaemia. However, of the 678 patients with fasting plasma glucose results of greater than 15.0 mmol/L, 25% were autoantibody positive or had hyperglycaemic symptoms. Insulin antibody-positive patients were 2.6 times more likely to be unable to achieve fasting plasma glucose concentrations of less than 15 mmol/L. 13 Plasma C-peptide concentrations are used to assess pancreatic b-cell failure as a marker of endogeneous insulin production. 14 LADA can be ruled out using a random serum C-peptide result, 15 levels being signi¢cantly lower in the autoimmune diabetes patients. Fasting and stimulated plasma C-peptide levels have also been shown to be decreased in LADA patients. 16 It may be possible to use features of insulin de¢ciency such as (relatively) high plasma glucose concentration with or without haemoglobin (Hb)A 1 c greater than 10% despite good compliance to treatment, and lower body mass index (BMI), age and C-peptide level in order to identify patients most likely to have LADA. 4, 10 Patients' preference A pilot survey has shown that the majority (83%) of patients would like a routine test 17 as they ¢nd it helps them to deal with their condition. Patients require a correct diagnosis in order to help them control their own diabetes. Health professionals would value the test to better inform treatment decisions. 17 
Treatment of patients with latent autoimmune diabetes in adults
Patients with type 2 diabetes and LADA masquerading as type 2 will often be prescribed sulphonylurea (SU) treatment. In fact, SU is recommended for people with type 2 diabetes who are not overweight or obese. This is similar to the early clinical picture in LADA. 18 However, this form of treatment may deplete the already low reserves of endogenous insulin. LADA patient given SU drugs have poor fasting glucose concentrations and higher levels of antibodies compared with those treated with insulin. 19--24 Type 2 patients who fail to respond to SU drugs are more likely to be those with LADA. 25 Therefore, with the correct diagnosis, SU treatment could be avoided in LADA patients.
There is an argument for the introduction of insulin very early in the disease process. Early studies in Japan 19--21 have suggested that LADA patients should start insulin within one year of diagnosis in order to maintain near-normal glycaemic control, and this treatment can prevent slowly progressive b-cell failure. Patients taking insulin had an improved C-peptide response (i.e. improved b-cell function and natural insulin production), stable HBA 1 c values and reduced autoantibody level. These ¢ndings have been supported by studies in Cuba 22 and China. 23 Insulin may have an e¡ect in slowing down the development of LADA even though this e¡ect is not seen in classical type 1 diabetes. 26 However, there is a need to validate these ¢ndings in a Caucasian population. Oral agents like glitazones have anti-in£ammatory activity and could potentially also be an e¡ective treatment for patients in the non-insulin-dependent stage of their diabetes. Rosiglitazone has been given in combination with insulin and was found to maintain C-peptide levels better than insulin alone. 23 Laboratory studies support an anti-in£ammatory role for glitazones which could be bene¢cial for people with LADA, especially given the moderate level of insulin resistance associated with LADA. Therefore, early identi¢cation of LADA may help to persuade patients that persistence with oral agents in isolation is likely to be futile, thus allowing for a smoother transition to insulin.
Conclusion
In summary, at present, the best detection method for LADA is the serum GAD antibody test. The use of this in monitoring all patients with type 2 diabetes who meet certain criteria 27 and who are not requiring insulin at diagnosis will ensure that patients are not o¡ered potentially detrimental treatment, are aware of their possible future need for insulin and that both the patient and their health-care provider are informed of the correct diagnosis. Plasma C-peptide can assist in the diagnosis. Treatment of patients with LADA is at an experimental stage, and more work is needed to determine whether insulin or glitazones (followed by insulin) or both is the best method. 23 Therefore, it is not yet proven that early diagnosis leading to early initiation of insulin will alter clinical outcomes, but it is only through greater awareness and future research that this question can be answered.
